Our mission is to change the trajectory of human health, one baby at a time

Mike Johnson is Chief Executive Officer of Infinant Health®, where he leads the company's mission to translate groundbreaking microbiome science into therapies that improve outcomes for infants. He is responsible for driving corporate strategy, fundraising, investor engagement, business development, and organizational growth, while ensuring the successful advancement of the company's scientific and clinical programs. Under his leadership, Infinant Health has strengthened its therapeutic development capabilities, expanded key strategic partnerships, and advanced INF108, an investigational microbiome therapeutic designed to prevent necrotizing enterocolitis (NEC) in preterm infants.

Known for his collaborative and execution-focused leadership style, Mike has built multidisciplinary teams both at Infinant Health and Cargill spanning research, clinical development, manufacturing, quality, and commercialization. He brings nearly two decades of experience building and scaling science-driven health and biotechnology businesses.

Prior to joining Infinant Health, he served as Global Managing Director for Cargill's Animal Health Technologies division, where he led a global organization of approximately 500 scientists, engineers, product developers, and commercial professionals responsible for developing and commercializing innovative health technologies worldwide.

Dr. Sylvester is a surgeon-scientist, innovator, and entrepreneur. He is a globally recognized expert in maternal and child health discovery and translation. As an innovator, he has started and advised numerous companies in product development and innovation across the spectrum of life sciences, including medical technology, therapeutics, and diagnostics. In addition, he has led multidisciplinary teams in both academia and industry in the development of technology platforms for translational application. Dr. Sylvester is a Professor of Surgery and Pediatrics at Lucile Packard Children's Hospital Stanford and Associate Dean of Maternal and Child Health Research at Stanford University School of Medicine. He has led a distinguished career in clinical care for infants born with a spectrum of congenital anomalies and is a recognized expert in newborn gut biology.

Dr. Sylvester is an experienced clinical trialist and was a leading member of the first team to successfully execute a prospective randomized NIH-sponsored clinical trial for the surgical treatment of necrotizing enterocolitis in critically ill, very low birth weight newborns. He has authored over 120 peer-reviewed publications and holds numerous patents for his novel discoveries.

Christian is a healthcare leader with more than 20 years of experience building high-performance organizations in the biotechnology, pharmaceutical, diagnostic, and medical device industries. He has successfully driven commercial operations and launched numerous pharmaceutical, diagnostic, and medical device products across multiple channels.

A dedicated leader with a passion for organizational growth, Christian has led healthcare companies through private equity, public offering, and acquisition life cycles. This includes ViaCell, a biotechnology company specializing in cord blood stem cells that was acquired by global health science leader PerkinElmer for $300M. As Senior Vice President at TherapeuticsMD, he earned 'Forbes Fast 500' recognition for healthcare revenue growth three years in a row, building the nation's largest women's health sales organization from inception and achieving a $1.7B market valuation after the company went public in 2016. In addition to the launch of three new drugs in four years, TherapeuticsMD leveraged disruptive channel innovation with the development of vitaCare Prescription Services, later acquired by GoodRx for $150M. Most recently, Christian served as President and Chief Commercial Officer at Dominion Aesthetic Technologies, where he led this robotic medical device company from 510K clearance through production and successful launch, garnering aesthetic industry awards and market recognition.

He earned his Master's in Management at Troy University and began his healthcare career at Eli Lilly & Company after serving as a Captain in the United States Air Force. 

Carrie McGuckin, RNC-NIC, is a neonatal healthcare and commercial leader with nearly two decades of experience spanning neonatal intensive care, clinical education, provider engagement, and healthcare sales. As Director of National Sales and Clinical Education at Infinant Health, she leads national commercial and educational initiatives that support the company's mission to improve infant health through microbiome science. Drawing on more than 14 years of NICU nursing experience, Carrie is positioned to partner with healthcare providers and health systems nationwide to advance the adoption of evidence-based interventions that improve outcomes for vulnerable infants.

Since joining Infinant Health in 2018, Carrie has played a key role in expanding awareness of the company's science-driven solutions while strengthening relationships across the neonatal community. She leads clinical education and site training efforts, collaborating closely with healthcare providers, internal teams, and clinical research partners to support the successful execution of clinical studies and future commercialization initiatives. Known for her ability to translate complex scientific evidence into practical clinical application, Carrie helps bridge the gap between research, provider adoption, and improved patient outcomes.

Arlene Fosmer is a senior biotechnology and health innovation executive with more than 20 years of experience spanning microbiome science, fermentation, product development, operations, quality, supply chain, and business strategy. She is an accomplished innovator with more than 15 granted and pending patents and a proven track record of bringing breakthrough technologies to market that have generated more than $1 billion in revenue. She currently serves as Chief Science Officer at Infinant Health, where she leads research and development, quality, operations, and supply chain teams focused on advancing clinical and new product development from strategy through commercialization.

Prior to Infinant Health, Arlene held multiple senior leadership positions at Cargill, including Managing Director of Supplements, Director of Innovation, Portfolio Manager, Senior Project Manager, and Principal Fermentation Scientist. Throughout her tenure, she led cross-functional global teams across sales, marketing, innovation, operations, and quality; managed large innovation portfolios and multimillion-dollar budgets; supported M&A, investment, and strategic partnership activities; and drove growth strategies across animal and human health specialty ingredients businesses with direct P&L responsibility. She also served on the boards of venture-stage companies and investment funds, including AnimalBiome, Infinant Health, and Seventure Health for Life II.

Known for combining deep scientific expertise with strategic business leadership, Arlene has successfully built and scaled innovation pipelines, led complex biotechnology and fermentation projects from bench through commercial manufacturing, and fostered high-impact collaborations with academic, industry, and investment partners. Her expertise spans microbial physiology, process development, regulatory strategy, intellectual property, CDMO management, cGMP quality oversight, and external scientific communications with partners, investors, and customers. In addition to her professional accomplishments, Arlene is deeply committed to mentoring and developing talent, with a particular passion for advancing women in science and leadership.

Mandy Kennedy is a senior commercial and operational executive with more than 25 years of leadership experience spanning biotechnology, health technologies, consumer packaged goods, and global food innovation. She currently serves as Chief Commercial Officer and Chief of Staff at Infinant Health, where she leads commercial strategy, organizational operations, and executive initiatives focused on advancing infant health through microbiome science.

Prior to Infinant Health, Mandy spent nearly a decade at Cargill in progressive global leadership roles, including Global Director of Customer Experience and Global Marketing Director for Cargill Health Technologies. She led international teams across North America and Europe, overseeing marketing, customer experience, training, customer service, and sales operations for leading health and nutrition brands including EpiCor, Diamond V, and Delacon.

Known for her strategic leadership, cross-functional collaboration, and ability to scale businesses, Mandy has successfully led commercialization efforts, organizational transformation initiatives, product launches, and customer innovation programs throughout her career. Earlier in her career, she held brand and innovation leadership roles at a number of CPG companies.

Mandy earned her Master of Business degree with a focus in Marketing from RMIT University in Melbourne, Australia, where she attended as a Rotary Ambassadorial Scholar.

Britta Heiss, Ph.D., is Director of Pharmaceutical and Translational Sciences at Infinant Health, where she provides scientific leadership for microbiome-based therapeutic development. Her work integrates microbial ecology, host-microbe interactions, nonclinical experimentation, clinical trial preparation, and regulatory science to support the advancement of interventions for vulnerable infants. She plays a central role in the development of INF108, Infinant Health’s investigational drug candidate for the prevention of necrotizing enterocolitis (NEC) in preterm infants.

Britta joined Infinant Health in 2021 as an R&D scientist, where her early work supported claim substantiation and research on microbiome-focused products. As the company expanded from consumer-facing products into pharmaceutical development, she helped build the scientific and regulatory foundation for therapeutic advancement, including IND-enabling studies, manufacturing-readiness activities, endpoint strategy, and drug product development in collaboration with CROs, CDMOs and company leadership.

In her current role, Britta is a primary scientific writer for major clinical and regulatory documents, including clinical protocols, pre-IND and IND content, and ODD documents. She also and manages areas of the intellectual property portfolio. Across these responsibilities, she serves as a scientific bridge between discovery research, nonclinical development, CMC, clinical operations, regulatory strategy, and intellectual property development.

Britta earned her Ph.D. from the University of California, Davis, where her research focused on how Bifidobacterium species establish and maintain populations within the infant gut microbiome.

Dr. Scottoline has extensive experience in translational research that focuses on the intersection of human milk biochemistry, nutritional therapeutics,  gut microbiome, and health outcomes in neonates. He is a Professor in the Division of Neonatology at the School of Medicine at Oregon Health and Science University (OHSU). OHSU maintains a level IV neonatal intensive care unit (NICU) that successfully treats the most difficult cases. Dr. Scottoline is an active physician-scientist who is deeply committed to raising the standard of care in the NICU. He earned his MD from Stanford University School of Medicine and his PhD from Stanford University and has been in practice for over 15 years. He is affiliated with the NEC Society, American Academy of Pediatrics (Sections on Neonatal-Perinatal Medicine, Advances in Therapeutics and Technology, and Critical Care), Society for Critical Care in Medicine, American  Association for the Advancement of Science, the NEC Biorepository, and the Neonatal Nutrition Collaborative. Dr. Scottoline has authored over 20 peer-reviewed publications related to the optimization of care in the NICU. Moreover, he is the principal investigator of ongoing studies investigating the role of probiotics and the infant gut microbiome in necrotizing enterocolitis (NEC). 

Dr. Sylvester is a surgeon-scientist, innovator, and entrepreneur. He is a globally recognized expert in maternal and child health discovery and translation. As an innovator, he has started and advised numerous companies in product development and innovation across the spectrum of life sciences, including medical technology, therapeutics, and diagnostics. In addition, he has led multidisciplinary teams in both academia and industry in the development of technology platforms for translational application. Dr. Sylvester is a Professor of Surgery and Pediatrics at Lucile Packard Children's Hospital Stanford and Associate Dean of Maternal and Child Health Research at Stanford University School of Medicine. He has led a distinguished career in clinical care for infants born with a spectrum of congenital anomalies and is a recognized expert in newborn gut biology.

Dr. Sylvester is an experienced clinical trialist and was a leading member of the first team to successfully execute a prospective randomized NIH-sponsored clinical trial for the surgical treatment of necrotizing enterocolitis in critically ill, very low birth weight newborns. He has authored over 120 peer-reviewed publications and holds numerous patents for his novel discoveries.

Christian is a healthcare leader with more than 20 years of experience building high-performance organizations in the biotechnology, pharmaceutical, diagnostic, and medical device industries. He has successfully driven commercial operations and launched numerous pharmaceutical, diagnostic, and medical device products across multiple channels.

A dedicated leader with a passion for organizational growth, Christian has led healthcare companies through private equity, public offering, and acquisition life cycles. This includes ViaCell, a biotechnology company specializing in cord blood stem cells that was acquired by global health science leader PerkinElmer for $300M. As Senior Vice President at TherapeuticsMD, he earned 'Forbes Fast 500' recognition for healthcare revenue growth three years in a row, building the nation's largest women's health sales organization from inception and achieving a $1.7B market valuation after the company went public in 2016. In addition to the launch of three new drugs in four years, TherapeuticsMD leveraged disruptive channel innovation with the development of vitaCare Prescription Services, later acquired by GoodRx for $150M. Most recently, Christian served as President and Chief Commercial Officer at Dominion Aesthetic Technologies, where he led this robotic medical device company from 510K clearance through production and successful launch, garnering aesthetic industry awards and market recognition.

He earned his Master's in Management at Troy University and began his healthcare career at Eli Lilly & Company after serving as a Captain in the United States Air Force. 

Dr. Knobil has been appointed as an Advisor to the Infinant Health Board, bringing more than 25 years of experience in pharmaceutical research and product development including global clinical research, medical affairs and patient safety in large pharma, biotech, and medtech. Dr. Knobil has strategically led research and development resulting in regulatory approval and the successful launch of blockbuster medicines.

Dr. Knobil was the first Chief Medical Officer at Agilent Technologies, the Chief Medical Officer and Head of Research and Development at Kaleido Biosciences, and Chief Medical Officer at GlaxoSmithKline. At GSK, she directed the development of multiple new chemical entities and product line extensions, including Flolan for Primary Pulmonary Hypertension and Advair for COPD. She held roles both domestically and in expat assignments in London and Shanghai, where she established the GSK clinical development organization in China. During her career, Kate led the development and delivery of presentations at regulatory agencies worldwide, including multiple FDA Advisory Committees. Dr. Knobil is currently the Chief Medical Officer for Altesa BioSciences and serves on the boards of Pliant Therapeutics, Inc., Marker Therapeutics, Inc., and Nimbus Therapeutics, LLC. 

Dr. Knobil earned a BA in Biology from Cornell University, her Doctor of Medicine degree from The University of Texas Southwestern Medical School, completed her internal medicine residency at the University of Michigan Medical School, and completed her fellowship in pulmonary and critical care medicine at Johns Hopkins University School of Medicine. 

Dr. Jordon is an Associate Professor of Pediatrics, Division of Neonatology, at Oregon Health & Science University School of Medicine and is the Principal Investigator who will be running the BeLONG pre-term safety trial in preterm infants for Infinant Health once it is approved. Dr. Jordan graduated from David Geffen School of Medicine at UCLA and specializes in the care of infants born prematurely and full-term infants who need intensive care. He is a published researcher with over 15 peer-reviewed papers.

Dr. Yuan is a pediatric gastroenterologist, author, and advocate for the health of infants and children. He received his MD from the Capital University of Medical Sciences in Beijing, The People’s Republic of China, and his PhD from the University of Auckland, New Zealand. A physician-scientist, he is the Co-Director of the Food Allergy Center at the Massachusetts General Hospital and Associate Professor of Pediatrics at Harvard Medical School, where he specializes in gastrointestinal food allergies in infants and children. Dr. Yuan is the leader of the large prospective birth cohort Gut Microbiome, Adiposity, and Probiotics (GMAP) study, which focuses on one of the earliest manifestations of food allergies in infancy, food protein-induced allergic proctocolitis (FPIAP).   

Dr. Pompliano has been appointed as an Advisor to the Infinant Health Board, offering his expertise in the pharmaceutical space as the company progresses along the pharmaceutical development path. Dr. Pompliano is a drug discovery scientist, entrepreneur and executive with >30 years of experience in the biopharmaceutical industry. Working with venture-capitalists and academicians, he creates scientifically precocious, game-changing new commercial enterprises based on exciting discoveries in academic science. 

Dr. Pompliano co-founded, and served as CSO, CIO or CEO of, Odyssey Therapeutics, Daros, Lodo Therapeutics (acquired by Zymergen) and Revolution Medicines (RVMD), and helped raise over $400m in Series A financing. He is currently co-founder and CEO of Donum Therapeutics. Earlier, as a senior executive at GlaxoSmithKline and Merck, he led drug discovery teams that produced pre-clinical credentials for >30 development candidates and five registered anti-infective (Recarbrio, Altabax) and oncology (Tykerb, Votrient, Promacta) drugs. As Owner of Sanderling Consulting LLC, he assists investors, companies, and philanthropies in setting drug discovery strategy, in executing the operations of preclinical discovery and development, and in evaluating pharmaceutical assets.

Dr. Pompliano earned the BS and PhD degrees in Chemistry from the University of Virginia and from Stanford University, respectively, and conducted research in enzymology and molecular biology as a National Institutes of Health Postdoctoral Fellow in Jeremy Knowles' laboratory at Harvard University. He has published more than 50 peer-reviewed papers in the areas of infectious diseases, cancer drug discovery, and mechanistic enzymology.

Jenn is a highly accomplished marketing executive with over 20 years of brand management expertise in both consumer-packaged goods and healthcare and possesses a formidable, proven track record of success. She has held marketing leadership roles across a variety of global organizations, including Unilever, L'Oreal, and German skincare company Beiersdorf, as well as within the private equity space, where she has consistently driven market share growth in highly commoditized categories. Most recently, Jenn was Head of Marketing for Aspira Women's Health, where she developed the marketing strategy to drive adoption, market expansion, and standard of care for gynecological health among health care professionals. Jenn earned her MBA from Northwestern University, Kellogg School of Management, and has a deep and broad understanding of brand building, strategic marketing, innovation development, and commercialization.

Dr. Henrick is responsible for developing and executing Infinant Health's discovery research programs to help shape the vision and long-term growth of the company through the oversight of an innovative research pipeline of first- or best-in-class therapies. She has served as Associate Director for the Foods for Health Institute at the University of California, Davis. Moreover, she has previously led the optimization of the world's fastest and most accurate point-of-care HIV1/2 diagnostic. Dr. Henrick has a BSc degree in biology and chemistry from Missouri State University, where she was an All-American Division 1 athlete, and a Ph.D. in medical science, specializing in Infection and Immunity, from McMaster University. Her doctoral work focused on the characterization of the innate immune systems in sensing and regulating human immunodeficiency virus-1 infection from mother to child. Dr. Henrick holds nine patents and has 41 peer-reviewed publications, including a recent Cell manuscript that was the first to show how the infant gut microbiome composition polarizes the immune system towards tolerance and away from phenotypes strongly associated with autoimmune and allergic diseases by directly impacting CD4+ T cell maturation. She received the International Milk Genomics Consortium's "Top Early Investigator Award" and currently serves as an Adjunct Assistant Professor in the Department of Lincoln Food Science and Technology at the University of Nebraska, Lincoln.

Dr. Bragg serves as Associate Professor of Pediatrics and Director of the NICU Follow-up Program and Cardiac Neurodevelopmental Program at a Level IV NICU in New York. As a neonatologist, she is passionate about optimizing neurodevelopmental outcomes through a collaborative, multidisciplinary approach to advancing children's health. Her research interests include rapid genomic sequencing in critically ill infants, assessing the impact of developmental programming on parental stress, and early identification of sensory processing disorders in high-risk infants. Through the accelerated research pathway of the American Board of Pediatrics, she completed a year of research fellowship in neonatal follow-up, during which time she received a grant to study the impact of plasticizers on very low birth weight infants. She has been designated as a Castle Connelly Top Doctor from 2019 to 2022 and has a wealth of experience in both leadership and administration. Dr. Bragg has held several roles on multiple medical committees addressing important hospital metrics.

During the COVID-19 pandemic, she participated in a leadership course offered by Harvard Business Publishing that focused on successfully leading in a VUCA (Volatile, Uncertain, Complex, Ambiguous) world. She received her MD from New York University School of Medicine and completed her pediatric residency and perinatal neonatal fellowship at the Icahn School of Medicine at Mount Sinai in New York.

Craig is responsible for driving revenue through executing sales strategies aligned with company goals and objectives throughout the US and North American Market. He has over 25 years of medical sales and leadership experience that includes building sales teams and producing dramatic revenue growth in private startups as well as large public companies. Most recently, he was the Sales Director at Aspira Women's Health, responsible for national growth initiatives focusing on women's gynecological health. Before that, he spent over a decade with Millennium Health from startup through several VC acquisitions.

Craig has led commercial organizations through novel product launches, is well-versed in health system needs, and is experienced in establishing a customer-centric approach while inspiring, empowering, and motivating elite sales executive performance.

Dr. Freeman received a Ph.D. in gastrointestinal physiology from the University of Calgary before completing postdoctoral training at the University of California, Davis. While there, she became interested in how science and technology successfully create real-world value. She completed a certificate in business development from the Graduate school of Management at the University of California, Davis, to work at the forefront of the successful translation of research from science to market. With this new perspective, she became one of the co-founders of the Milk Bioactives Program and focused on building and managing multidisciplinary teams centered on the translation and commercialization of scientific discoveries from the program.

Dr. Freeman then spent two years as a manager of a national public-private partnership (Foods for Health Ireland) in Ireland before returning to the University of California, Davis, as the Associate Director of Business Development at the Foods for Health Institute and became a co-founder of Infinant Health, to open the door to commercializing the Institute's pioneering technology. She now focuses full-time on the company as the Director of Intellectual Property and Regulatory Affairs to help commercialize the technology developed at the University of California, Davis.

Dr. Qualter received a Master’s in Nursing from Columbia University. She was a Clinical Research Nurse Practitioner within the Division of Pediatric Blood and Marrow Transplantation at the Children's Hospital of New York-Presbyterian at Columbia University Medical Center. She was responsible for conducting pediatric oncology phase I clinical trials and institutional pediatric blood and marrow transplantation protocols. Her passion for clinical research led her to medical school, where she graduated cum laude from Albany Medical College. Dr. Qualter then returned to the Children's Hospital of New York Presbyterian for her pediatrics residency, followed by a fellowship in neonatal-perinatal medicine at Mount Sinai Medical Center.

Before Infinant Health, she worked as an attending neonatologist for Mednax at Monmouth Medical Center of RWJBarnabas Health, where she was responsible for opening and running its first clinical trial. Her passion lies in caring for extremely premature infants and optimizing their care and outcomes through the best nutrition options. 

Dr. Antonio is the southern California Clinical Implementation Director at Infinant Health. He also serves as Director of Neonatal Transport and Outreach and Associate Medical Director of the regional NICU at Miller Children's & Women's Hospital in Long Beach, California, where he oversees the operations, program development, and staff training specific to critically ill neonates in transport. His commitment to improving clinical and patient outcomes comes from his designation as a master training in TeamSTEPPS®, designed to optimize the use of information, clinicians, and resources to achieve optimal outcomes. He brought this experience to many referring hospitals and established Neonatal Transport service lines across southern California. As Associate Director, he cofounded the Extremely Low Birth Weight (ELBW) program. Dr. Antonio has a DO from the University of Medicine and Dentistry in New Jersey and completed his residency in pediatrics at the Goryeb Children's Hospital in Morristown, NJ. He completed a fellowship in neonatology at Cohen's Children's Medical Center in New York, known for its level IV NICU.

Dr. Antonio was a research fellow at the NIH, where his population health research focused on drug abuse and immune deficiency. His scholarly research during his fellowship included newborn screening for primary immune deficiencies. Dr. Antonio's research interests include neonatal transport medicine, high-frequency ventilation, pulmonary hypertension, chronic lung disease, neonatal resuscitation, newborn screening, and point-of-care ultrasound.

Dr. Adhikari is responsible for educating Infinant Health's scientific mission to physicians and health systems, helping them adopt the incredible advances to protect our most precious patients. Before joining Infinant Health, Dr. Adhikari was a strategic consultant in the Healthcare division of Huron Consulting Group and later became a pediatrician in Chicago, IL. She received her MD from The Chicago Medical School and completed her pediatric residency at Rush University Medical Center.

As a pediatrician, she completed an Ethics Fellowship from the University of Chicago, which she used to teach Northwestern University medical students about healthcare disparities, and received an Excellence in Teaching award for this work. She sees patients at The Northwestern Children's Practice in Chicago, IL.  

Dr. Hight, a highly skilled board-certified Pediatrician, is the Atlanta Clinical Implementation Director at Infinant Health. She also serves as a Pediatrician in the Children’s Healthcare of Atlanta network. A champion for maternal and child health, she is well regarded in the community. Dr. Hight has been named a Charlotte Magazine Top Doctor numerous times and is a multi-year recipient of the Parent Magazine parent choice award. Dr. Hight obtained her undergraduate and medical degree from Emory University with honors. She attended pediatric residency at Atrium Health Levine Children’s Hospital, which she led as the fourth-year Chief Resident. Dr. Hight worked as a clinical faculty instructor in the Department of Pediatrics at the University of North Carolina School of Medicine while serving children in private practice for over a decade. She sought to positively impact lives on a larger scale by branching into healthcare administration. First, as Medical Director implementing clinical quality improvement initiatives and most recently as Chief Medical Officer of a large health center, she transformed the patient experience, reducing medical errors and quantifiably raising the standard of care.

Dr. Hight is a passionate family advocate and ardent supporter of utilizing her extensive medical training and comprehensive experience to reduce health inequities through disease prevention.

Dr. Streimish is a highly accomplished medical professional, with a wealth of experience in the field of neonatal-perinatal medicine. As the Clinical Implementation Director for the New England area, she is responsible for overseeing the implementation of new medical practices and protocols, ensuring that patients receive the highest level of care. She began her journey in medicine in New Jersey, where she completed a joint BA/MD degree, followed by a pediatric residency and fellowship in neonatal-perinatal medicine. Throughout her career, she has worked tirelessly to coordinate prenatal and postnatal care and has devoted her career to working in Newborn ICUs and Special Care Nurseries in Boston and the surrounding areas, providing care to the most vulnerable and critically ill newborns.

Dr. Streimish is also committed to staying current with the latest developments in neonatal-perinatal medicine and is active in research to improve the care of newborns. She continues to be a respected leader in her field and is dedicated to providing the best possible care to her patients and their families.

Pallavi provides oversight of quality and product safety across Infinant Health's supply chain, focusing on co-manufacturing and co-packaging the hospital product vials and consumer powder sachets. As a CfPIE (Center for Professional Innovation and Education), CMC (Chemical, Manufacturing, and Controls), and Biopharmaceutical Development Certified Professional, she brings exceptional operational and regulatory expertise to the organization. Her expertise provides successful approaches and strategies to meet regulatory compliance requirements for FDA, EU, and International Conference for Harmonization (ICH). Pallavi's experience includes leading GFSI (Global Food Safety Initiative) and NSF Dietary Supplement certification efforts in various manufacturing environments.

She is also an ASQ Certified Quality Engineer who has led operational excellence initiatives to optimize consumer satisfaction utilizing Continuous Improvement tools. Pallavi has a degree in food biochemistry from the University of California, Davis, and a mini-MBA in Biopharma Innovation from Rutgers University Business School.

Derek is responsible for developing data analytics and reporting tools that support decision-making. His team supports executives and partners within the commercial organization. He is responsible for analyzing sales performance, budget management, variable compensation, territory planning, sales technology, and people analytics. Before joining Infinant Health, Derek served as Head of Commercial Operations and Analytics for Aspira Women's Health. Before that, he worked for over 30 years with Medtronic in various key roles, including Finance Reporting Manager and Senior Marketing Analyst. He also helped build several departments from inception and created and implemented a finance training program for the marketing team. Moreover, he has experience in contracts, supply chain, and distributor sales operations. 

Fei brings over 15 years of achievements in business analytics, digital marketing, brand management, and e-commerce. She has worked across a wide variety of industries, including healthcare, consumer products, and retail at organizations such as Blue Diamond Growers, Gap, Inc., and Target. Fei's broad range of experience includes helping brands widen their leadership gap and launching new brands to achieve significant revenue and profit growth. An accomplished brand leader and strategic thinker, Fei's skills include developing brand positioning based on meaningful insights and creating integrated, relevant cross-channel marketing plans to drive profitable business growth. Fei holds an MBA from the University of Michigan Ross School of Business. 

Sabrina is a high-performing marketing leader with 10+ years’ experience in the healthcare industry developing go-to-market strategies that create awareness, adoption, engagement, and retention to increase market share and fuel growth. Most recently, Sabrina served as Director of Marketing at XACT Robotics where she led the development of product positioning and messaging, launched several new brand trademarks, and overhauled the company’s digital marketing channels. Prior to XACT, Sabrina spent 12 years at PDI Healthcare transitioning the company from a commodity brand to a recognized market leader for infection prevention through a company rebranding, thought leadership content, industry partnerships, and integrated marketing communication programs. Sabrina holds her master’s in integrated marketing from Marist College.

Melanie comes to Infinant Health with nearly twenty years’ experience in a wide variety of product and commercial marketing roles in consumer goods and the medical device space. Prior to joining Infinant Health, she most recently worked with Hologic’s Breast and Skeletal Health division, as the commercial marketer for the Breast Surgery and Specimen Radiography portfolio of products. At Infinant Health, she will develop best in class marketing strategic and tactical plans that deliver on commercial revenue and business goals. She received her MBA with a concentration in International Business from Sacred Heart University.

Louis is an operations professional with 10+ years of experience in the computing and life science industries. At Infinant Health, Louis leads 3PL relationships, raw material and packaging procurement, production, and fulfillment. Louis excels at collaborating cross-functionally to ensure total delivered costs are maximized, rigorous product quality standards are upheld, and operational efficiencies are enhanced through the value stream. Before joining Infinant Health, Louis spent 6 years with Intel Corporation’s Business Operations division focusing on strategic Fortune 100 growth account’s forecasting and revenue tracking.

Jonathan is an interdisciplinary microbiome scientist committed to the advancement of live biological therapeutics and personalized health technologies. He is responsible for managing and executing upon Infinant’s product portfolio strategy in concert with the clinical, commercialization, and operations teams. Prior to joining Infinant Health, Jonathan contributed to the development of next-gen immunotherapy technologies at Prellis Biologics and Nanotein Technologies as a lead scientist. Outside of the laboratory, he has lead product development for non-alcoholic beverage brands like Mary’s Alchemy and The Free Spirits Company. Jonathan earned his Ph.D. from Rice University with an emphasis on elucidating interkingdom interactions between the fungus Candida albicans and anaerobic bacteria found throughout the gut. success. She has held marketing leadership roles across a variety of global organizations, including Unilever, L'Oreal, and German skincare company Beiersdorf, as well as within the private equity space, where she has consistently driven market share growth in highly commoditized categories. Most recently, Jenn was Head of Marketing for Aspira Women's Health, where she developed the marketing strategy to drive adoption, market expansion, and standard of care for gynecological health among health care professionals. Jenn earned her MBA from Northwestern University, Kellogg School of Management, and has a deep and broad understanding of brand building, strategic marketing, innovation development, and commercialization.

Lizabeth Kurjiaka has nearly 20 years of experience balancing customer needs and business objectives to deliver results successfully and consistently in regulated industries for medical devices, combination drug products, and aircraft engines. She executes with sense-minded decision-making and applies engineering acumen, risk/benefit analysis, and critical problem-solving to lead upstream and downstream outcomes. Before joining Infinant Health, Lizabeth held a dual role at Teleflex Medical as Director of Strategic Initiatives and Quality Manager, where she was responsible for product development activities and quality production for globally commercialized hemostatic products. 

She helped increase production capacity, introduce new technology systems, and expand indications. She has held other previous roles in research and development, quality, and program management at both large-scale companies, such as Boston Scientific and Medtronic, as well as startup companies. 

Kendall is a leader in clinical development planning and operations with ten years of experience in program management. She is motivated to develop collaborative project teams, shape programs to achieve their purpose swiftly, and focus on a patient-centric approach to treatment. Before joining Infinant Health, Kendall served as Associate Director, Strategy and Operations at Arvinas, Inc., where she was responsible for the ARV-471 breast cancer drug development program. Kendall helped guide the Arvinas team through a partnership arrangement with Pfizer and to globally operationalize the drug in various phase I/II studies to develop a path towards a new drug application and life cycle management. Kendall has also worked as Global Program Manager at Takeda Pharmaceuticals and as Project Manager, Drug Development at Kura Oncology. She has a master's in healthcare administration from Cornell University as well as a PMP certification.

Dr. Duar is a microbiome scientist with over a decade of hands-on experience devising and evaluating microbiome-based products for key indications. At Infinant Health, she has successfully generated key data that serves as the foundation for the mechanism of action and superiority of B. infantis EVC001. She is the author of over 20 peer-reviewed publications. Dr. Duar has an MSc. degree in food science and technology with an emphasis in analytical chemistry from the University of Nebraska, Lincoln, and a Ph.D. specializing in microbiome science and host-microbial symbiosis from the University of Alberta. She is the Associate Director of Product Marketing and the subject matter expert for Infinant Health's current and future products. In addition, she manages the product life cycles, penetration of the market, and customer relevancy.

Dr. Melnyk has nearly 15 years of experience as both a microbiologist and a bioinformatics scientist working in academia and industry. His primary areas of scientific expertise are in anaerobic microbial physiology, host-microbe interactions, and comparative genomics. Dr. Melnyk has published 23 papers in these areas, including 6 first-author papers. He was awarded the prestigious Life Sciences Research Fellowship for plant-microbe research he conducted at the University of British Columbia and University of California, Davis. Most recently, Dr. Melnyk worked at Pivot Bio, where he built a team of bioinformatics scientists and led several successful projects during a time of rapid growth.

At Infinant Health, he leads all computational components of the discovery platform, leveraging metagenomics, comparative genomics, and metabolomics to drive product development. Dr. Melnyk holds his Ph.D. in microbiology from the University of California, Berkeley and was the recipient of the Philomathia Graduate Fellowship.